IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Autor: Adeline Miranda, Dan Lupo, Federico Mingozzi, Xavier M. Anguela, Joseph Silverberg, Karen Huang, Heena Beck, Saghana Muraleetharan, Béatrice Marolleau, Fanny Collaud, Laetitia van Wittengerghe, Sean M. Armour, Christian Leborgne, Elena Barbon, Sandrine Delignat, Jeffrey M. Alexander, Hayley Hanby, Victoria Daventure, Giuseppe Ronzitti, Sébastien Lacroix-Desmazes, Anna Fabiano, Daniel M. Cohen

Publikováno v: Nature Medicine
Nature Medicine, Nature Publishing Group, 2020, 26 (7), pp.1096-1101. ⟨10.1038/s41591-020-0911-7⟩
Nature Medicine, 2020, 26 (7), pp.1096-1101. ⟨10.1038/s41591-020-0911-7⟩

Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in humans1,2, and block liver transduction3–5 and vector readministration6; thus, they represent a major limitation to in vivo gene therapy. Strategies aimed at ov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff04724b6af379a7e9370adc25a9aa43
https://hal.archives-ouvertes.fr/hal-03031762